Dr Michelle Tempest and Dr Karen Sayal reveal in this July 2019  #LaingBuisson article promising opportunities investing in  #immunotherapy treatments

Cancer therapeutic landscape is shifting to more distinct and personalised immunotherapy treatments.

With a market expected to almost triple by 2025, several biotech firms are in early #clinicaltrials.

Opportunities arise in

- novel combinations of check-point inhibitors: engineered proteins that bind to cancer cells and indirectly signal an ‘auto-destruct’ response from the immune system

- cellular based immunotherapy that involves, for part, re-infusing specific expanded immune cells (ACT, adoptive cell transfer)

Challenges remain because of the toxicity risk and the high costs associated.

https://www.linkedin.com/feed/update/urn:li:activity:6557267033044590592/